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To estimate susceptibility to the swine-origin influ-
enza A(H3N2) variant virus (A(H3N2)v) in the German 
population, we investigated cross-reactive antibod-
ies against this virus and factors associated with 
seroprotective titre using sera from representative 
health examination surveys of children and adoles-
cents (n = 815, 2003–06) and adults (n = 600, 2008–
10). Antibodies were assessed by haemagglutination 
inhibition assay (HI); in our study an HI titre ≥ 40 was 
defined as seroprotective. We investigated associated 
factors by multivariable logistic regression. Overall, 
41% (95% confidence interval (CI): 37–45) of children 
and adolescents and 39% (95% CI: 34–44) of adults 
had seroprotective titres. The proportion of people 
with seroprotective titre was lowest among children 
younger than 10 years (15%; 95% CI: 7–30) and high-
est among adults aged 18 to 29 years (59%; 95% CI: 
49–67). Prior influenza vaccination was associated 
with higher odds of having seroprotective titre (odds 
ratio (OR) for children and adolescents: 3.4; 95% CI: 
1.8–6.5; OR for adults: 2.4; 95% CI: 1.7–3.4). Young 
children showed the highest and young adults the low-
est susceptibility to the A(H3N2)v virus. Our results 
suggest that initial exposure to circulating seasonal 
influenza viruses may predict long-term cross-reac-
tivity that may be enhanced by seasonal influenza 
vaccination. 
Introduction
Pigs can serve as hosts for the reassortment of influ-
enza viruses of different origins (avian, human and 
swine) which involves the risk of emergence of new, 
genetically different influenza viruses that may infect 
humans. In addition, influenza viruses in pigs do not 
develop as much genetic diversity in a given time 
period as those in humans, resulting over time in diver-
gent antigenic characteristics between viruses circulat-
ing in swine and humans that may make humans more 
susceptible to swine viruses [1]. When such zoonotic 
swine influenza viruses are isolated from humans, 
they are called variant viruses [2]. The emergence of 
the pandemic influenza A(H1N1)pdm09 virus in 2009 
confirmed the risk posed by zoonotic influenza viruses 
emerging from pigs.
More than 300 infections with a variant influenza 
A(H3N2) virus (A(H3N2)v) have been recorded in the 
United States (US) since 2011, and most cases occurred 
in 2012 [3]. Most influenza A(H3N2)v infections 
occurred outside of the influenza season in children, 
and the course and severity of illness were similar to 
that of seasonal influenza. Most of the infected per-
sons reported to have attended agricultural fairs where 
they had either direct or indirect contact with pigs. 
Limited human-to-human transmission of the A(H3N2)v 
virus may have occurred as some cases in 2011 did not 
have any recent history of contact with pigs [4].
The A(H3N2)v virus is a triple reassortant A(H3N2) virus 
that acquired the matrix protein gene of the A(H1N1)
pdm09 virus [5,6]. It is closely related to human 
A(H3N2) virus strains, represented by the vaccine ref-
erence strain A/Wuhan/359/95, that circulated among 
humans in the mid-1990s until 1997 [5]. The observed 
age-related pattern of influenza A(H3N2)v infections 
in the US is most likely due to the similarity of the 
haemagglutinin of the A(H3N2)v virus to that of A/
Wuhan/359/95-like viruses as most cases were born 
after 1997 and not exposed to such human A(H3N2) 
viruses. The acquisition of the matrix gene after the 
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Figure 1 
Reverse cumulative distribution curve of haemagglutination inhibition antibody titres against influenza A/Wisconsin/12/2010, 
































Reverse cumulative distribution curve of haemagglutination inhibition antibody titres against influenza A/Wisconsin/12/2010, 
by age group, children and adolescents, Germany, 2003–2006 (n = 815)
































pandemic in 2009, possibly resulting in increased 
swine–human transmissibility of the virus, may 
explain the increasing number of A(H3N2)v infections. 
The low level of cross-reactive antibodies observed 
among young children and some adult age groups in 
seroepidemiologic studies in Canada, Japan, Norway, 
the United Kingdom (UK), and the US, may pose a risk 
of pandemic emergence of the A(H3N2)v virus [7-11]. A 
vaccine virus has been developed in case an influenza 
A(H3N2)v virus vaccine needs to be produced [7,12].
No data are available on the prevalence of cross-
reactive antibodies against the A(H3N2)v virus in the 
population of Germany and most of Western Europe. 
While infections with the A(H3N2)v virus have not been 
reported in Europe to date, this cannot be excluded 
in the future, and further adaptation of the virus to 
humans, involving increased ability of human-to-
human spread, is possible. In a seroepidemiological 
study among adults, we showed that age-related sero-
prevalence patterns of antibodies against the A(H1N1)
pdm09 virus in Germany did not follow those observed 
in other countries in Europe and North America [13]. 
Such variability may, among other reasons, be due to 
the circulation of different seasonal influenza virus 
subtypes in the different countries or to different vac-
cination histories in the studied populations.
To estimate the susceptibility to influenza A(H3N2)v in 
the German population, we assessed the prevalence of 
cross-reactive antibodies against this virus as a cor-
relate of pre-existing protection and investigated the 
association between characteristics of the study popu-
lation and the prevalence of cross-reactive antibodies.
Methods
Serum samples
The serum samples used for this study originated 
from two population-wide, representative health 
examination surveys conducted in Germany. For the 
adult population we used sera from the first wave of 
the German Health Interview and Examination Survey 
for Adults (DEGS), conducted from November 2008 
through December 2011 [13,14]. DEGS is part of the 
national health monitoring and combines periodic 
health surveys with a longitudinal study of adults 18 
years or older. Participants (8,152 persons) were ran-
domly selected from the general population by using 
a stratified two-stage cluster sample approach. The 
study included completion of standardised question-
naires, physical examinations and tests, and a blood 
sample (available for 7,116 of the 8,152 participants). 
For our adult study population, we used an age-strat-
ified (three age groups) random sub-sample of DEGS 
sera (n = 600, 200 in each age group) collected from 
November 2008 through April 2010 [13].
To assess the seroprevalence in children and adoles-
cents we used sera from the nationwide, population-
based German Health Interview and Examination 
Survey for Children and Adolescents (KiGGS) that 
assessed persons between 0 and 17 years of age. Data 
and blood samples (1–17 years of age) were collected 
from 2003 through 2006 using an approach similar to 
DEGS [15]. From the 17,641 participants in the original 
study, a simple random sub-sample of those for whom 
blood samples were available (n = 815 of 14,387 par-
ticipants) was used for our study. The reason why the 
sub-sample for children and adolescents was larger 
than the adult sample was that these sera were also 
used in a study of another research group and were 
thawed and aliquoted at the same time; this allowed 
us to increase our power for the analysis.
Serological analysis
We performed haemagglutination inhibition (HI) testing 
to analyse sera for cross-reactive antibodies against 
three influenza A(H3N2) virus strains. Influenza A/
Wisconsin/12/2010 (A/Wisconsin) was used as rep-
resentative for the A(H3N2)v virus, the primary target 
of the study. To confirm the specificity of measured 
antibody titres against A/Wisconsin, we also tested 
sera for antibodies against two other A(H3N2) virus 
strains. One of them, A/Niedersachsen/59/2007 (A/
Niedersachsen), was a swine A(H3N2) virus circulating 
among pigs in Germany that caused one human infec-
tion in Germany in 2009 [16] and is closely related to the 
A(H3N2) swine viruses that emerged in Europe around 
1980 after reassortment between human A(H3N2) 
viruses and swine viruses of subtype A(H1N1). The 
second strain used for comparison, A/Perth/16/2009 
(A/Perth), was the A(H3N2) vaccine strain used in the 
influenza seasons 2010/11 and 2011/12, representing 
human influenza A(H3N2) viruses circulating recently 
[16]. The reference strains A/Wisconsin/12/2010 and 
A/Perth/16/2009 were obtained from the World Health 
Organization (WHO) Collaborating Centre in London, 
UK. A/Niedersachsen was isolated in Lower Saxony 
and belongs to the influenza virus strain selection of 
the German National Influenza Reference Centre. 
The HI tests were performed according to standard 
WHO protocol as described before [13]. Prior to test-
ing, each serum was treated with receptor-destroying 
enzyme (Cholera filtrate, Sigma, Germany) to inacti-
vate non-specific inhibitors, achieving a final serum 
dilution of 1:10. The sera were then diluted serially 
twofold to detect titres up to ≥ 1,280. All samples were 
tested twice to account for the variability of results in 
the HI assay.
Statistical analysis
For statistical analyses, the following age groups were 
used: 18–29 (born 1979–92), 30–59 (born 1949–80) 
and ≥ 60 years (born before 1951) for adults and 0–9 
(born 1994–2006), 10–13 (born 1990–96) and 14–17 
years (born 1986–92) for children and adolescents. As 
end point we used the geometric mean of two antibody 
measurements as a single observation. We defined a 
titre ≥ 40 as seroprotective in line with other studies and 
with definitions used for evaluating influenza vaccines 
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(the 50% seroprotective threshold) [17]. Titres < 10 were 
considered negative and were assigned a value of 5 for 
further calculations.
We calculated the proportion of persons with seropro-
tective titre and the geometric mean titre (GMT) with 
95% confidence intervals (CI) in each age group for each 
influenza strain. For A/Wisconsin, we also calculated 
proportions with titres ≥ 10, ≥ 20, ≥ 80, ≥ 160 and ≥ 320. 
We examined the effect of different variables on the 
dichotomous variable ‘titre ≥40’, using logistic regres-
sion to obtain odds ratios (OR) with 95% CI for each 
influenza strain. As a first step, we conducted univari-
able regression analysis to identify potential factors 
associated with seropositivity. Independent variables 
with a p value < 0.25 based on the Wald test were 
considered for the multivariable analysis [18]. Manual 
stepwise forward selection based on p values from the 
Wald test was then used to obtain the final model. A 
p value < 0.05 was considered statistically significant. 
All variables in the final model were tested for possi-
ble two-way interactions. The variables investigated in 
the logistic regression analysis included demographic 
characteristics, history of influenza vaccination, year 
when blood sample was taken, region of residence in 
Germany, community size, factors related to health and 
social status and to living conditions (Table 1). 
Statistical analyses for children and adolescents were 
conducted by using survey weights based on cross-clas-
sifications by age, sex, residence in Eastern or Western 
Germany and nationality (German vs non-German) to 
Table 1 
Independent variables investigated in the univariable logistic regression analysis among adults and children and adolescents, 
Germany, 2003–10
Variable name Description Population
Sex Female, male Adults, children and adolescents
Age group
18–29, 30–59, ≥ 60 years Adults
0–9, 10–13, 14–17 years Children and adolescents
Sampling year
2008, 2009, 2010; 2008-09, 2010 Adults
2003, 2004, 2005, 2006 Children and adolescents
Prior influenza vaccination
Seasonal or pandemic 2009 
(based on vaccination card or self-reporting) Adults
Seasonal (based on vaccination card) Children and adolescents
Number of influenza vaccinations Based on vaccination card Children and adolescents
Body weight Body weight in kg Adults, children and adolescents
Body mass index Cut-off values: > 25, > 30, > 33, > 40, < 18 Adults
Nationality German vs non-German Adults
Migrant Migrant vs non-migrant Children and adolescents
Geographical area Former East-, West Germany (Berlin included in East Germany) Children and adolescents
Smoking
Smoker; amount of smoking Adults
Participant is smoker;
at least one parent is smoker; friends are smokers Children and adolescents
Community size Four categories for number of inhabitants;  two categories for urban vs rural Adults, children and adolescents
Social status Three categories Adults, children and adolescents
Education
Three categories Adults
Education of parents in three categories Children and adolescents
Health status Based on self-reporting Adults, children and adolescents
Any chronic disease Having any chronic disease Adults, children and adolescents
Alcohol intake Risk drinking; amount of alcohol Adults
Number of persons living in household Living alone vs 2, 3, 4, 5 or 6 persons Children and adolescents
Sibling(s) in household 0 vs 1, 2, 3 or 4 siblings Children and adolescents
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account for differences between the design-weighted 
net sample and German population characteristics [15]. 
Original survey weights could not be used for the adult 
sample as the sera for our study were selected from a 
subgroup of the adult study population for which the 
survey weights were calculated. Based on German pop-
ulation characteristics of 2010 (data source: German 
Federal Statistical Office), we calculated weights based 
on sex and age group for adults, and these were used 
for the calculation of overall proportions and GMTs. In 
our study, 43 of the 180 study locations (sample points) 
of the original adult study were included. Two of 16 
German states were not represented in our sample (the 
city states Bremen and Hamburg). As those city states 
comprise less than 5% of the total German population, 
we can assume that the adult sample was sufficient to 
represent German geographic characteristics [13]. The 
analyses accounted for the two-stage cluster design of 
the surveys.
All analyses were carried out with STATA software 
version 12.1 (StataCorp, College Station, TX, US). The 
study was approved by the Ethics Committee of Charité 
University Medicine, Berlin, Germany.
Results
Adults
The unweighted median age of the 600 participants 
included in the adult study was 47 years (range: 
18–84) and 50% were female. Overall, 43% of partici-
pants (unweighted proportion) had been vaccinated at 
least once in their lifetime with an influenza vaccine 
(seasonal or pandemic 2009). Among the 600 adults, 
44% had cross-reactive antibodies at titre ≥ 40 against 
A/Wisconsin. The overall prevalence of cross-reactive 
antibodies at titre ≥ 40, weighted for sex and age group, 
was 39% (95% CI: 34–44) (Table 2).
For A/Wisconsin, the highest proportion of persons 
with titre ≥ 40 and the highest GMT were seen in the 
youngest age group (18–29 years). In the age group 
30–59 years, the proportion was lower, whereas among 
persons aged 60 years and older, the proportion was 
again higher, but did not reach the level of the young-
est age group. For A/Perth, the pattern across the age 
groups was similar to A/Wisconsin with lower propor-
tions in all age groups. For A/Niedersachsen, the pro-
portions with seroprotective titre and the GMTs were 
highest in the age group 30–59 years. 
The distribution of different cut-off values for antibody 
titres against A/Wisconsin in the three age groups was 
explored in reverse cumulative distribution curves 
(Figure 1). The pattern of difference between age groups 
was observed at all cut-off values. Titres declined rap-
idly after titre 40, and no titres > 320 were measured.
The final multivariable logistic regression model for all 
three strains contained age group, sex and prior influ-
enza vaccination as independent variables (Table 3). 
Sex was included in the final model to show that it was 
not associated with seroprotective titres; inclusion did 
not relevantly change ORs for other variables. Those 60 
years and older had higher odds of having a seropro-
tective titre compared with the 30–59 year-olds in the 
univariable analysis for A/Wisconsin (OR: 1.6; 95% CI: 
1.1–2.4; p = 0.014). This difference was not significant 
after adjustment for prior influenza vaccination. Prior 
influenza vaccination was shown to be a factor associ-
ated with seroprotective titre for A/Wisconsin and A/
Perth with the highest OR for A/Perth and lower for A/
Wisconsin; the association for A/Niedersachsen was 
not significant. There were no significant interactions 
between the variables of the final models.
Children and adolescents
The unweighted median age of persons in this study 
was 13 years (range: 2–17) and 46% were female. 
Overall, 9.6% of the study participants (unweighted 
proportion) had been vaccinated at least once in their 
lifetime with a seasonal influenza vaccine. Among the 
815 children and adolescents, 42% had cross-reac-
tive antibodies at titre ≥ 40 against A/Wisconsin. The 
weighted overall prevalence of cross-reactive antibod-
ies at titre ≥ 40 was 41% (95% CI: 37–45) (Table 4). For 
the three influenza strains investigated, the lowest 
proportion with seroprotective titre and the lowest 
Table 2 
Haemagglutination inhibition antibody titres against influenza A(H3N2), by age group and virus strain, adults, Germany, 
2008–2010 (n = 600)
Age group 
(years) n
Proportion with titre ≥ 40 (95% CI) GMT (95% CI)
A/Wisconsin A/Perth A/Niedersachsen A/Wisconsin A/Perth A/Niedersachsen
18–29 200 59 (49–67) 24 (17–31) 23 (16–31) 33 (28–39) 12 (10–15) 15 (13–17)
30–59 200 30 (24–38) 16 (13–21) 49 (40–57) 17 (15–20) 9 (8–10) 27 (23–32)
≥ 60 200 42 (35–49) 23 (18–29) 26 (19–35) 23 (21–26) 14 (11–16) 18 (16–21)
Overall 600 39 (34–44) 19 (17–22) 37 (31–43) 21 (19–23) 11 (10–12) 22 (19–24)
CI: confidence interval; GMT: geometric mean titre.
Overall proportions and overall GMTs are weighted (see Methods).
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GMT were seen among those younger than 10 years, 
with proportions and GMTs increasing with increasing 
age. The overall proportion with seroprotective titre for 
A/Perth and A/Niedersachsen was less than 10%. 
The distribution of different cut-off values for antibody 
titres against A/Wisconsin in the three age groups was 
explored using reverse cumulative distribution curves 
(Figure 2). The pattern of difference between age 
groups was observed at all cut-off values, with rapidly 
declining titres after titre 40 and no measurable titres 
> 320.
The final multivariable logistic regression model 
included age group, sex and prior influenza vaccination 
as independent variables for all three strains (Table 5). 
For A/Perth, there was no significant association with 
age. Significant associations between prior vaccination 
and seroprotective titres were shown for each tested 
strain, with the highest OR for A/Perth, followed by A/
Wisconsin and A/Niedersachsen. Female sex was asso-
ciated with higher odds of having a seroprotective titre 
for A/Wisconsin and A/Niedersachsen. There were no 
significant interactions between the variables of the 
final models.
Discussion
Using sera from two representative health examination 
surveys in the German population including adults, 
children and adolescents, we have shown that children 
younger than 10 years (in 2003–06, i.e. those born 
1994–2006) had the lowest prevalence of cross-reactive 
antibodies against the A(H3N2)v virus representative 
A/Wisconsin. Among children aged 10 years and older, 
adolescents and adults, the prevalence was markedly 
higher. The pattern of differences between age groups 
could be observed at many titre cut-off values, not just 
at the level defined as seroprotective. The observed 
Table 3
Adjusted effects of associated factors on the odds of haemagglutination inhibition antibody titre ≥ 40 against influenza 
A(H3N2), by virus strain, adults, Germany, 2008–2010 (n = 582)
Variable
A/Wisconsin A/Perth A/Niedersachsen
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age group (years)
18–29 REF NA NA REF NA NA REF NA NA
30–59 0.28 0.16–0.50 < 0.001 0.53 0.32–0.90 0.019 3.2 1.9–5.4 < 0.001
≥ 60 0.36 0.20–0.64 0.001 0.53 0.31–0.90 0.019 1.0 0.61–1.70 0.954
Sex
Male REF NA NA REF NA NA REF NA NA
Female 1.2 0.85–1.80 0.320 0.97 0.63–1.50 0.903 1.2 0.78–1.80 0.434
Prior influenza vaccination 2.4 1.7–3.4 < 0.001 4.3 2.6–7.2 < 0.001 1.5 0.99–2.20 0.055
CI: confidence interval; NA: not applicable; OR: odds ratio; REF: reference group.
Participants with missing data (n = 18) were excluded.
Table 4
Haemagglutination inhibition antibody titres against influenza A(H3N2), by age group and virus strain, children and 
adolescents, Germany, 2003–2006 (n = 815) 
Age group 
(years) n
Proportion with titre ≥ 40 (95% CI) GMT (95% CI)
A/Wisconsin A/Perth A/Niedersachsen A/Wisconsin A/Perth A/Niedersachsen
0–9 62 15 (7–30) 2.2 (0.5–9.4) 0.6 (0.0–4.2) 13 (10–17) 6.1 (5.5–6.8) 5.7 (5.1–6.3)
10–13 353 37 (31–44) 3.0 (1.6–5.5) 3.6 (2.0–6.5) 21 (19–24) 6.3 (6.0–6.7) 7.9 (7.4–8.5)
14–17 400 47 (42–52) 3.9 (2.3–6.5) 12.0 (9.0–16.0) 27 (24–29) 6.5 (6.1–6.9) 11 (10–12)
Overall 815 41 (37–45) 3.4 (2.3–5.0) 8.1 (6.3–10.0) 23 (22–25) 6.4 (6.1–6.7) 9.3 (8.8–9.8)
CI:  confidence interval; GMT: geometric mean titre. 
Proportions and GMTs are weighted (see Methods).
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pattern of age-specific seroprevalence of cross-reac-
tive antibodies against the A(H3N2)v virus is consist-
ent with findings from countries in Asia (Japan), Europe 
(Norway, UK) and North America (Canada, US) [7-11]. 
The levels of cross-reactive antibody titres against the 
influenza A(H3N2)v virus in the different age groups 
were consistent with the likelihood of exposure to sea-
sonal A/Wuhan/359/95-like influenza strains. Likewise, 
cross-reactive antibody titre levels against the contem-
porary human influenza A(H3N2) virus (A/Perth) and 
the swine influenza A(H3N2) virus (A/Niedersachsen) 
were in line with the likelihood of exposure to related 
circulating seasonal influenza strains and confirm the 
specificity of our results regarding the A(H3N2)v virus.
Several mechanisms may explain the observed prev-
alences of cross-reactive antibodies against the 
A(H3N2)v virus and the highest proportions with 
seroprotective titre among those aged 14–17 and 18–29 
years. Young adults are at high risk for infection as their 
contact patterns result in frequent exposure to circulat-
ing seasonal influenza viruses. The 14–29 year-olds in 
our study are likely to have been infected at a young age 
with the A/Wuhan/359/95-like human A(H3N2) virus 
that is very similar to A(H3N2)v. This may have repre-
sented the initial exposure to influenza viruses, result-
ing in long-lasting immunity. The first infection with an 
influenza virus is believed to influence and dominate 
immune responses to later infections (original antigenic 
sin theory) [19,20]. Although they had the opportunity 
of exposure to A/Wuhan/359/95-like human A(H3N2) 
viruses, older adults had lower antibody levels against 
the A(H3N2)v virus. Lower frequency of influenza infec-
tions among older adults may explain this observation. 
In addition, the initial childhood exposure of these 
adults to influenza was to viruses different from the 
A(H3N2)v virus. Children younger than 10 years were 
least likely to have been exposed to influenza viruses 
similar to the A(H3N2)v virus, which explains why the 
antibody levels in this group were the lowest.
Any influenza vaccination in the lifetime of our study 
participants (after adjustment for age and sex) was 
positively associated with having a seroprotective titre 
of cross-reactive antibodies against all three investi-
gated strains. This effect was strongest for the human 
influenza A(H3N2) virus A/Perth and weaker for the 
swine-related influenza A(H3N2) viruses A/Wisconsin 
and A/Niedersachsen, which is plausible considering 
that A/Wisconsin and A/Niedersachsen are less related 
to human vaccine strains than A/Perth.
In the final model, female children and adolescents 
had slightly higher odds of having a seroprotective 
titre against the A(H3N2)v and swine A(H3N2) virus. 
This may be explained by a generally stronger immune 
response to infections and vaccination in women, 
and sex-related differences in HI titres after seasonal 
influenza vaccination have been described before [21]. 
Such an effect was not observed among adults, nor 
with the human A(H3N2) virus strain among children 
and adolescents.
The proportions of adults with seroprotective titre 
against the A(H3N2)v virus differed significantly 
between the age groups 30–59 and ≥ 60 years. Similar 
observations have been made by others for the 
A(H3N2)v virus [10,11] and also for seasonal H3N2 and 
H1N1 subtypes where, among others possible causes, 
the priming infection of a person and prior influenza 
vaccination were suggested to be strong determi-
nants of such a pattern [20,22-24]. Using information 
about prior influenza vaccination in a multivariable 
logistic regression model, we have shown that, in our 
Table 5 
Adjusted effects of associated factors on the odds of haemagglutination inhibition antibody titre ≥ 40 against influenza 
A(H3N2), by virus strain, children and adolescents, Germany, 2003–2006 (n = 815) 
Variable
A/Wisconsin A/Perth A/Niedersachsen
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age group (years)
0–9 REF NA NA REF NA NA REF NA NA
10–13 3.2 1.3–8.0 0.013 1.3 0.27–6.60 0.713 5.7 0.69–47.0 0.105
14–17 4.6 1.8–12.0 0.001 1.8 0.40–7.90 0.442 20.0 2.6–151 0.004
Sex
Male REF NA NA REF NA NA REF NA NA
Female 1.5 1.0–2.0 0.025 0.78 0.33–1.80 0.549 2.7 1.5–4.9 0.001
Prior influenza vaccination 3.4 1.8–6.5 < 0.001 5.4 2.2–14.0 < 0.001 2.2 1.1–4.6 0.028
CI: confidence interval; NA: not applicable; OR: odds ratio; REF: reference group.
The regression models are weighted (see Methods).
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population, this difference was most probably a result 
of the higher proportion of elderly people with prior 
influenza vaccination (one of the risk groups for whom 
seasonal influenza vaccination is recommended in 
Germany).
Our study had several limitations. Serum samples origi-
nated from two different population surveys carried out 
in different time periods over several years (2003–06 
and 2008–10) and therefore under the influence of dif-
ferent circulating human influenza viruses. Considering 
this and the exposure history of the population after 
the surveys were carried out, caution should be applied 
when using our results to predict age-related suscepti-
bility in the population today. Some of the age groups 
of KiGGS and DEGS participants overlap when they are 
considered as birth cohorts. This overlap may explain 
the similar prevalence of seroprotective titres among 
those aged 14–17 and 18–29 years. 
HI is used as a correlate for immunity against infection 
with influenza virus, but beside cross-reactive antibod-
ies, many other biological mechanisms influence the 
actual immune response of a person (e.g. T-cell medi-
ated immunity) [25,26] and thus susceptibility to influ-
enza viruses. Increased HI titres may not necessarily 
prevent higher infection rates. We demonstrated this in 
an earlier study conducted in Germany, where the age 
group with the highest pre-pandemic titres against the 
A(H1N1)pdm09 virus had the highest infection rates 
with this virus [13]. It cannot be assumed that prior 
influenza vaccination necessarily provides true pro-
tection against infection with the A (H3N2)v virus as 
studies have shown that prior vaccination against sea-
sonal influenza may be associated with a higher risk 
of becoming infected with a pandemic influenza strain 
(A(H1N1)pdm09) [27-30]. A recent study did not show 
the 2011/12 seasonal trivalent inactivated influenza 
vaccine to have a cross-protective effect against the 
A(H3N2)v virus in seronegative ferrets [31]. This may 
have implications for young children not yet infected 
by influenza virus because a seasonal influenza vac-
cine without an A(H3N2)v virus component would most 
probably not confer any immunity against the A(H3N2)
v virus among them. In addition, the assumption that 
an HI titre ≥ 40 indicates 50% seroprotection is based 
on studies in adults. Recent studies suggest that a 
titre ≥ 40 or higher may be used as a correlate of 50% 
seroprotection for children aged 6–17 years [32], but 
higher titres may be needed to predict at least 50% 
protection in younger age groups [33]. Furthermore, 
compared to younger adults, HI titres seem to be less 
reliable in predicting protection in the elderly and in 
certain risk groups [34].
Our results indicate that young children have the high-
est susceptibility to infection with the A(H3N2)v virus. 
In case of increased sustained human-to-human trans-
mission of the virus, these children may contribute to 
the rapid spread of the A(H3N2)v virus as transmission 
among children plays a major role in the propagation of 
the spread of influenza [35]. They are also at high risk 
for severe disease from influenza infections. A large 
proportion of the population 10 years and older has 
cross-reactive antibodies at potentially seroprotective 
level and thus, based on this correlate for immunity, 
may be at low risk for A(H3N2)v infection. Our results 
suggest that the first exposure to circulating seasonal 
influenza viruses in a person’s lifetime may predict 
their long-term cross-reactive antibody response. 
These cross-reactive antibodies can be boosted by 
vaccination and possibly by exposure to seasonally cir-
culating influenza viruses. Further studies may further 
our understanding of the effect of seasonal influenza 
viruses on the serological immune response. 
Acknowledgements
We thank Katharina Alpers for critically reading the manu-
script and Michaela Diercke for her helpful comments. This 
study would not have been possible without the support and 
participation of the staff at the Robert Koch Institute con-
ducting the surveys and the laboratory analysis. This project 
was funded by the Robert Koch Institute.
The study was approved by the Ethics Committee of Charité 




B. Blümel contributed to the overall design of the study, an-
alysed the data, and drafted the manuscript. B. Schweiger 
contributed to the study design, supervised the laboratory 
analysis, and reviewed the manuscript. M. Dehnert and I. 
Czogiel contributed to the design of the analysis, super-
vised data analysis, and reviewed the manuscript. S. Buda, 
A. Reuss contributed to the study design and reviewed the 
manuscript. P. Kamtsiuris, M. Schlaud, C. Poethko-Müller, 
and M. Thamm provided the data and sera for the study and 
reviewed the manuscript. W. Haas contributed to the overall 
design of the study and the design of the analysis, and re-
viewed the manuscript.
References 
1. Myers KP, Olsen CW, Gray GC. Cases of swine influenza 
in humans: a review of the literature. Clin Infect Dis. 
2007;44(8):1084-8. http://dx.doi.org/10.1086/512813 
PMID:17366454
2. World Health Organization (WHO). Standardization of 
terminology for the influenza virus variants infecting humans: 
Update. Geneva: WHO; 2014. Available from: http://www.who.
int/influenza/gisrs_laboratory/terminology_variant/en/
3. Centers for Disease Control and Prevention (CDC). Case count: 
detected U.S. human infections with H3N2v by state since 
August 2011. Atlanta: CDC; [Accessed 14 Sep 2014]. Available 
from: http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm
4. Jhung MA, Epperson S, Biggerstaff M, Allen D, Balish A, Barnes 
N, et al. Outbreak of variant influenza A(H3N2) virus in the 
United States. Clin Infect Dis. 2013;57(12):1703-12. http://
dx.doi.org/10.1093/cid/cit649 PMID:24065322
5. Lina B, Bouscambert M, Enouf V, Rousset D, Valette M, van 
der Werf S. S-OtrH3N2 viruses: use of sequence data for 
description of the molecular characteristics of the viruses 
and their relatedness to previously circulating H3N2 human 
viruses. Euro Surveill. 2011;16(50):20039. PMID:22221493
6. Lindstrom S, Garten R, Balish A, Shu B, Emery S, Berman L, et 
al. Human infections with novel reassortant influenza A(H3N2)v 
9www.eurosurveillance.org
viruses, United States, 2011. Emerg Infect Dis. 2012;18(5):834-
7. http://dx.doi.org/10.3201/eid1805.111922 PMID:22516540
7. Centers for Disease Control and Prevention (CDC). Antibodies 
cross-reactive to influenza A (H3N2) variant virus and impact 
of 2010-11 seasonal influenza vaccine on cross-reactive 
antibodies - United States. MMWR Morb Mortal Wkly Rep. 
2012;61(14):237-41. PMID:22495226
8. Hoschler K, Thompson C, Casas I, Ellis J, Galiano M, 
Andrews N, et al. Population susceptibility to North 
American and Eurasian swine influenza viruses in England, 
at three time points between 2004 and 2011. Euro Surveill. 
2013;18(36):20578. http://dx.doi.org/10.2807/1560-7917.
ES2013.18.36.20578 PMID:24079379
9. Kishida N, Imai M, Xu H, Taya K, Fujisaki S, Takashita E, et al. 
Seroprevalence of a novel influenza A (H3N2) variant virus in 
the Japanese population. Jpn J Infect Dis. 2013;66(6):549-51. 
http://dx.doi.org/10.7883/yoken.66.549 PMID:24270150
10. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca 
V, Scheifele DW, et al. Cross-reactive and vaccine-induced 
antibody to an emerging swine-origin variant of influenza A 
virus subtype H3N2 (H3N2v). J Infect Dis. 2012;206(12):1852-
61. http://dx.doi.org/10.1093/infdis/jis500 PMID:22872731
11. Waalen K, Kilander A, Dudman SG, Ramos-Ocao R, Hungnes O. 
Age-dependent prevalence of antibodies cross-reactive to the 
influenza A(H3N2) variant virus in sera collected in Norway in 
2011. Euro Surveill. 2012;17(19):20170. PMID:22607964
12. European Centre for Disease Prevention and Control (ECDC). 
Update - Swine-origin triple reassortant influenza A(H3N2) 
variant viruses in North America. Risk assessment. Stockholm: 
ECDC; 2012. Available from: http://www.ecdc.europa.eu/en/
publications/publications/1208-ter-rapid-risk-assessment-
influenza-ah3n2-us.pdf
13. Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause 
G, et al. Prevalence of antibodies to 2009 pandemic influenza 
A (H1N1) virus in German adult population in pre- and post-
pandemic period. PLoS ONE. 2011;6(6):e21340. http://dx.doi.
org/10.1371/journal.pone.0021340 PMID:21701598
14. Scheidt-Nave C, Kamtsiuris P, Gößwald A, Hölling H, 
Lange M, Busch MA, et al. German health interview and 
examination survey for adults (DEGS) - design, objectives and 
implementation of the first data collection wave. BMC Public 
Health. 2012;12(1):730. http://dx.doi.org/10.1186/1471-2458-
12-730 PMID:22938722
15. Kurth BM, Kamtsiuris P, Hölling H, Schlaud M, Dölle R, Ellert 
U, et al. The challenge of comprehensively mapping children’s 
health in a nation-wide health survey: design of the German 
KiGGS-Study. BMC Public Health. 2008;8(1):196. http://dx.doi.
org/10.1186/1471-2458-8-196 PMID:18533019
16. Robert Koch Institute (RKI). Bericht zur Epidemiologie der 
Influenza in Deutschland, Saison 2011/12. [Report on the 
epidemiology of influenza in Germany, season 2011/12]. Berlin: 
RKI; 2012. ISBN 978-3-89606-247-5. German. Available from: 
https://influenza.rki.de/Saisonberichte/2011.pdf
17. Katz JM, Hancock K, Xu X. Serologic assays for influenza 
surveillance, diagnosis and vaccine evaluation. Expert Rev 
Anti Infect Ther. 2011;9(6):669-83. http://dx.doi.org/10.1586/
eri.11.51 PMID:21692672
18. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful 
selection of variables in logistic regression. Source Code Biol 
Med. 2008;3(1):17. http://dx.doi.org/10.1186/1751-0473-3-17 
PMID:19087314
19. Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from 
pandemic influenza. J Theor Biol. 2011;288:29-34. http://
dx.doi.org/10.1016/j.jtbi.2011.08.003 PMID:21856313
20. Kucharski AJ, Gog JR. The role of social contacts and original 
antigenic sin in shaping the age pattern of immunity to 
seasonal influenza. PLOS Comput Biol. 2012;8(10):e1002741. 
http://dx.doi.org/10.1371/journal.pcbi.1002741 PMID:23133346
21. Klein SL, Pekosz A. Sex-based biology and the rational 
design of influenza vaccination strategies. J Infect Dis. 
2014;209(Suppl 3):S114-9. http://dx.doi.org/10.1093/infdis/
jiu066 PMID:24966191
22. Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, 
Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents 
of New South Wales, Australia, after the first pandemic 
wave in the 2009 southern hemisphere winter. PLoS ONE. 
2010;5(9):e12562. http://dx.doi.org/10.1371/journal.
pone.0012562 PMID:20830210
23. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, 
Broman M, et al. High frequency of cross-reacting antibodies 
against 2009 pandemic influenza A(H1N1) virus among 
the elderly in Finland. Euro Surveill. 2010;15(5):19478. 
PMID:20144443
24. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc 
S, Chan T, et al. Immuno-epidemiologic correlates of pandemic 
H1N1 surveillance observations: higher antibody and lower 
cell-mediated immune responses with advanced age. J Infect 
Dis. 2011;203(2):158-67. http://dx.doi.org/10.1093/infdis/
jiq039 PMID:21288814
25. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson 
W, Carman W, et al. Cellular immune correlates of protection 
against symptomatic pandemic influenza. Nat Med. 
2013;19(10):1305-12. http://dx.doi.org/10.1038/nm.3350 
PMID:24056771
26. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras 
MM, Hillaire ML, Vogelzang-van Trierum SE, et al. Human 
cytotoxic T lymphocytes directed to seasonal influenza A 
viruses cross-react with the newly emerging H7N9 virus. J Virol. 
2014;88(3):1684-93. http://dx.doi.org/10.1128/JVI.02843-13 
PMID:24257602
27. Rosella LC, Groenwold RH, Crowcroft NS. Assessing the impact 
of confounding (measured and unmeasured) in a case-control 
study to examine the increased risk of pandemic A/H1N1 
associated with receipt of the 2008-9 seasonal influenza 
vaccine. Vaccine. 2011;29(49):9194-200. http://dx.doi.
org/10.1016/j.vaccine.2011.09.132 PMID:22001885
28. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, 
Boulianne N, Hottes TS, et al. Association between the 2008-
09 seasonal influenza vaccine and pandemic H1N1 illness 
during Spring-Summer 2009: four observational studies 
from Canada. PLoS Med. 2010;7(4):e1000258. http://dx.doi.
org/10.1371/journal.pmed.1000258 PMID:20386731
29. Viboud C, Simonsen L. Does seasonal influenza vaccination 
increase the risk of illness with the 2009 A/H1N1 pandemic 
virus? PLoS Med. 2010;7(4):e1000259. http://dx.doi.
org/10.1371/journal.pmed.1000259 PMID:20386730
30. Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, 
Sabaiduc S, et al. Randomized controlled ferret study to 
assess the direct impact of 2008-09 trivalent inactivated 
influenza vaccine on A(H1N1)pdm09 disease risk. PLoS 
ONE. 2014;9(1):e86555. http://dx.doi.org/10.1371/journal.
pone.0086555 PMID:24475142
31. Houser KV, Katz JM, Tumpey TM. Seasonal trivalent inactivated 
influenza vaccine does not protect against newly emerging 
variants of influenza A (H3N2v) virus in ferrets. J Virol. 
2013;87(2):1261-3. http://dx.doi.org/10.1128/JVI.02625-12 
PMID:23115290
32. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della 
Cioppa G, et al. Hemagglutination inhibition antibody titers as 
a correlate of protection for inactivated influenza vaccines in 
children. Pediatr Infect Dis J. 2011;30(12):1081-5. http://dx.doi.
org/10.1097/INF.0b013e3182367662 PMID:21983214
33. Ng S, Fang VJ, Ip DKM, Chan KH, Leung GM, Peiris JSM, et 
al. Estimation of the association between antibody titers 
and protection against confirmed influenza virus infection 
in children. J Infect Dis. 2013;208(8):1320-4. http://dx.doi.
org/10.1093/infdis/jit372 PMID:23908481
34. Reber A, Katz J. Immunological assessment of influenza 
vaccines and immune correlates of protection. Expert Rev 
Vaccines. 2013;12(5):519-36. http://dx.doi.org/10.1586/
erv.13.35 PMID:23659300
35. Wallinga J, Teunis P, Kretzschmar M. Using data on social 
contacts to estimate age-specific transmission parameters 
for respiratory-spread infectious agents. Am J Epidemiol. 
2006;164(10): 936-44. http://dx.doi.org/10.1093/aje/kwj317 
PMID:16968863
